Positive effects of antitumor drugs in combination with propolis on canine osteosarcoma cells (spOS-2) and mesenchymal stem cells

Autor(es)

Bernardino, Pedro Negri ^[1] ; Oliveira Bersano, Paulo Ricardo ^[2] ; Lima Neto, Joao Ferreira ^[3] ; Sforcin, Jose Mauricio ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Inst Biosci, Campus Botucatu, Sao Paulo - Brazil

^[2] Univ Estadual Ceara, Fac Vet Med, Lab Pathol & Legal Vet Med, Fortaleza, Ceara - Brazil

^[3] Univ Sao Paulo, Sch Pharmaceut Sci, Pharmaceut Biochem Technol Dept, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BIOMEDICINE & PHARMACOTHERAPY; v. 104, p. 268-274, AUG 2018.
• Citações Web of Science: 0

Resumo

The combination of lower concentrations of antitumor drugs (carboplatin - CARB, doxorubicin - DOX, and methotrexate - MET) with propolis was investigated against canine osteosarcoma (spOS-2) and mesenchymal stem cells (MSC) in vitro. The mechanism of action in the combinations was analyzed. spOS-2 cells were incubated up to 72 h with propolis (50 mu g/ml) alone or in combination with CARB (10-400 mu mol/l), DOX (0.5-2 mu mol/l) or MET (50-200 mu mol/l). Cell viability was assessed by MTT assay, apoptosis/necrosis by flow cytometry, and MSC was incubated with the optimum combination. Propolis alone exerted no cytotoxic action against spOS-2 cells, whereas CARB (400, 200 and 100 mu mol/l) exhibited the highest cytotoxic effects comparing to DOX and MET. The combination of propolis with the lowest concentrations of CARB led to better results comparing to CARB alone, which was not observed using DOX and MET. Apoptosis was involved in the action of propolis + CARB in spOS-2 cells. MSC were not affected by CARB/propolis, indicating that the cytotoxic action of the combination was specific to tumor cells but not to normal ones. Propolis improved the action of CARB against spOS-2 cells using lower concentrations of this drug, without affecting MSC. These findings are relevant and indicate a possible application of propolis in OSA treatment. (AU)

• Processo FAPESP: 09/53493-9 - Expressão in vitro da cicloxigenase-2 (COX2) no osteossarcoma exposto a inibidor seletivo da COX2
• Beneficiário: Noeme Sousa Rocha
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 12/21158-9 - Possível ação sinérgica da própolis em associação com quimioterápicos frente a células de osteosarcoma canino in vitro
• Beneficiário: Pedro Negri Bernardino
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica